Managed Healthcare Executive September 4, 2024
Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they’re not spending money on something that’s not going to work.
As more data become available about how glucagon-like peptide 1 (GLP-1) receptor agonists impact the metabolic system, demand for and use of GLP-1 drugs are expected to grow. GLP-1 drugs have gained a lot of attention for their ability to help people lose weight but also for their ability to reduce the risk factors associated with obesity.
Although some insurers — such as Blue Cross Blue Shield of Michigan — have said they plan to stop coverage of GLP-1 drugs for obesity, others are considering adding such coverage. In Mercer’s Survey of Health and Benefits Strategies...
Today's Sponsors
Today's Sponsor